The financial strain on biotech companies is forcing them to re-evaluate their investment strategies.
Rallybio and
Monopar are two such companies adjusting their plans to extend their limited resources. Rallybio is halting its preclinical investments, while Monopar is shifting its focus to radiopharmaceuticals.
Rallybio has been through significant changes over the past 14 months. The company decided to abandon its lead candidate in favor of a second-generation asset within the same therapeutic area. Although this new candidate promises easier delivery and manufacturing, the transition has delayed its progress towards a registrational trial. To conserve resources for its leading program, Rallybio has reduced its workforce by 45% as of February. In its first-quarter earnings report, the company announced it would stop investing in its preclinical pipeline. Rallybio remains optimistic about the potential of its candidates and will seek external funding, such as partnerships, to advance them.
The preclinical pipeline for Rallybio includes
RLYB332, a long-lasting variant of
RLYB331, an anti-
Matriptase-2 antibody. Rallybio plans to present nonclinical data on this candidate, which it believes could be a top-notch treatment for diseases caused by
iron overload, in the latter half of the year.
Monopar, on the other hand, has completed its pivot to radiopharmaceuticals. Initially, radiopharmaceuticals were not part of Monopar's strategy when it went public in 2019. However, the potential of a preclinical anti-
uPAR antibody led to a strategic shift. By linking the antibody to radioisotopes, Monopar has established a radiopharmaceutical program, offering both imaging and therapeutic possibilities. Consequently, Monopar is discontinuing non-radiopharma assets, including the Phase 1b
cancer candidate
camsirubicin. As of the end of March, Monopar reported having just under $9 million, enough to sustain operations until at least the following summer. During this period, Monopar intends to continue human studies of its imaging asset and progress its first therapeutic radiopharmaceutical into clinical trials.
Despite Monopar's stock price rarely exceeding $1 over the past year, the company has highlighted recent acquisitions in the radiopharma sector by major players like
AstraZeneca,
Bristol Myers Squibb,
Eli Lilly, and
Novartis, each exceeding $1 billion, to remind investors of the sector's potential.
Meanwhile,
RAPT Therapeutics is facing setbacks with two phase 2 trials recently put on hold by the FDA. In its first-quarter earnings report, RAPT disclosed that it would close and unblind a phase 2a study testing
zelnecirnon in
asthma patients and a phase 2b study in
atopic dermatitis patients. The clinical hold followed a severe adverse event: a patient in the atopic dermatitis trial experienced
liver failure, necessitating organ transplantation. This adverse effect was potentially linked to zelnecirnon. Despite these challenges, CEO Brian Wong, M.D., Ph.D., expressed confidence that sufficient data would be available to determine the drug's future. RAPT aims to finish analyzing the data by the third quarter of the year while continuing to investigate the adverse event.
In summary, biotech companies like Rallybio and Monopar are realigning their strategies to cope with financial constraints. While Rallybio is cutting back on preclinical investments, Monopar is embracing radiopharmaceuticals. RAPT Therapeutics, dealing with clinical holds, is working to understand the implications of adverse events in their trials.
How to obtain the latest research advancements in the field of biopharmaceuticals?
In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!
